Keyphrases
Lenalidomide
100%
Phase II Study
100%
Peripheral T-cell Lymphoma
100%
Previously Untreated
100%
Romidepsin
100%
Overall Response Rate
60%
Complete Response
60%
Initial Treatment
40%
Angioimmunoblastic T-cell Lymphoma
40%
Dehydration
20%
Hyperglycemia
20%
Chemotherapy
20%
Hypertension
20%
Overall Survival
20%
Anemia
20%
Thrombocytopenia
20%
Poor Prognosis
20%
Progression-free Survival
20%
Cytotoxic Chemotherapy
20%
Duration of Response
20%
Neutropenia
20%
Hypokalemia
20%
6-cycles
20%
Nonhematologic
20%
Hyponatremia
20%
Hematotoxicity
20%
Hypoalbuminemia
20%
Free Combination
20%
Chemotherapy-free
20%
Pharmacology, Toxicology and Pharmaceutical Science
Peripheral T Cell Lymphoma
100%
Romidepsin
100%
Lenalidomide
100%
Chemotherapy
40%
Angioimmunoblastic T Cell Lymphoma
40%
Cytotoxic Chemotherapy
20%
Overall Survival
20%
Infection
20%
Progression Free Survival
20%
Biological Product
20%
Hypokalemia
20%
Hyperglycemia
20%
Anemia
20%
Thrombocytopenia
20%
Neutropenia
20%
Hyponatremia
20%
Hypoalbuminemia
20%
Medicine and Dentistry
Lenalidomide
100%
Peripheral T-Cell Lymphoma
100%
Romidepsin
100%
Chemotherapy
40%
Angioimmunoblastic T-Cell Lymphoma
40%
Biological Product
20%
Overall Survival
20%
Progression Free Survival
20%
Neutropenia
20%
Hypokalemia
20%
Anemia
20%
Thrombocytopenia
20%
Cytotoxic Chemotherapy
20%
Infection
20%
Hyponatremia
20%
Hyperglycemia
20%
Hypoalbuminemia
20%